drugset / Trial / NCT00003353

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

NCT00003353 ↗

Treatment

Summary

RATIONALE: High-dose chemotherapy may destroy the amyloid-producing cells in bone marrow. Peripheral stem cell transplantation PURPOSE: Phase II trial to study the effectiveness of high dose melphalan plus peripheral stem cell transplantation in treating patients who have primary systemic amyloidosis.

Timeline

Start
1998-11-16
Primary completion
2002-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule — Intravenous
Background filgrastim Protein / enzyme biologic — Subcutaneous

Indications